$242 Million is the total value of Opaleye Management Inc.'s 42 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 36.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HROW | Buy | HARROW HEALTH INC | $40,360,000 | +66.4% | 3,343,817 | +0.3% | 16.67% | +52.4% |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $26,830,000 | +11.7% | 6,465,000 | +8.2% | 11.08% | +2.4% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $19,845,000 | +1221.2% | 810,000 | +123.8% | 8.20% | +1110.6% |
| TELA | Buy | TELA BIO INC | $17,351,000 | +50.6% | 2,036,551 | +23.9% | 7.17% | +38.0% |
| CRNX | CRINETICS PHARMACEUTICALS INC | $13,184,000 | +5.3% | 671,300 | 0.0% | 5.44% | -3.5% | |
| CYTK | Sell | CYTOKINETICS INC | $12,742,000 | +7.2% | 263,000 | -13.1% | 5.26% | -1.8% |
| KROS | Buy | KEROS THERAPEUTICS INC | $12,087,000 | +58.5% | 321,300 | +16.4% | 4.99% | +45.2% |
| TARA | Buy | PROTARA THERAPEUTICS INC | $7,993,000 | -10.0% | 2,708,067 | +0.9% | 3.30% | -17.6% |
| CDXS | Sell | CODEXIS INC | $6,999,000 | -48.1% | 1,155,000 | -10.4% | 2.89% | -52.4% |
| TCON | Buy | TRACON PHARMACEUTICALS INC | $6,997,000 | -15.2% | 4,190,000 | +1.6% | 2.89% | -22.3% |
| CUTR | CUTERA INC | $6,735,000 | +21.6% | 147,700 | 0.0% | 2.78% | +11.4% | |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $6,248,000 | +73.9% | 635,000 | +40.7% | 2.58% | +59.3% |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $6,086,000 | +25.8% | 900,300 | -14.0% | 2.51% | +15.3% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $5,318,000 | +190.9% | 1,661,784 | +78.1% | 2.20% | +166.5% |
| ETON | Buy | ETON PHARMACEUTICALS INC | $5,294,000 | -17.9% | 2,521,000 | +2.4% | 2.19% | -24.8% |
| INBX | Sell | INHIBRX INC | $5,254,000 | -21.5% | 292,700 | -50.4% | 2.17% | -28.1% |
| MRUS | Sell | MERUS N.V. | $5,072,000 | -33.7% | 253,200 | -25.1% | 2.10% | -39.3% |
| PCVX | VAXCYTE INC | $4,560,000 | +10.3% | 190,000 | 0.0% | 1.88% | +1.1% | |
| XOMA | Sell | XOMA CORP DEL | $4,442,000 | -24.2% | 248,000 | -5.7% | 1.84% | -30.5% |
| URGN | Buy | UROGEN PHARMA LTD | $3,307,000 | +69.2% | 397,500 | +66.5% | 1.37% | +55.1% |
| LQDA | Buy | LIQUIDIA CORPORATION | $3,065,000 | +34.8% | 563,500 | +8.1% | 1.27% | +23.5% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS INC | $2,820,000 | +24.3% | 350,700 | +7.9% | 1.16% | +13.9% |
| STXS | Sell | STEREOTAXIS INC | $2,802,000 | -27.5% | 1,556,800 | -25.9% | 1.16% | -33.6% |
| FBIO | Sell | FORTRESS BIOTECH INC | $2,579,000 | -5.4% | 2,999,000 | -7.6% | 1.06% | -13.3% |
| PRQR | Buy | PROQR THERAPEUTICS NV | $2,318,000 | +8.8% | 3,115,000 | +13.7% | 0.96% | -0.4% |
| GRPH | Buy | GRAPHITE BIO INC | $1,830,000 | +44.7% | 577,250 | +25.5% | 0.76% | +32.6% |
| Buy | THESEUS PHARMACEUTICALS INC | $1,280,000 | +615.1% | 220,650 | +583.1% | 0.53% | +553.1% | |
| IMPL | Buy | IMPEL PHARMACEUTICALS INC | $1,243,000 | -7.8% | 255,250 | +76.5% | 0.51% | -15.6% |
| New | ASTRIA THERAPEUTICS INC | $1,207,000 | – | 133,500 | +100.0% | 0.50% | – | |
| MODULAR MEDICAL INC | $1,135,000 | -20.5% | 275,422 | 0.0% | 0.47% | -27.1% | ||
| ALLK | New | ALLAKOS INC | $939,000 | – | 153,500 | +100.0% | 0.39% | – |
| CMRX | Sell | CHIMERIX INC | $704,000 | -76.3% | 365,000 | -74.5% | 0.29% | -78.3% |
| Buy | JOURNEY MEDICINE CORP | $638,000 | -30.6% | 259,293 | +5.5% | 0.26% | -36.5% | |
| MOR | New | MORPHOSYS AGsponsored ads | $609,000 | – | 121,015 | +100.0% | 0.25% | – |
| EDAP | New | EDAP TMS SAsponsored adr | $588,000 | – | 71,300 | +100.0% | 0.24% | – |
| NPCE | Buy | NEUROPACE INC | $436,000 | -2.2% | 116,324 | +29.1% | 0.18% | -10.4% |
| LUMO | Buy | LUMOS PHARMA INC | $412,000 | +148.2% | 46,576 | +116.4% | 0.17% | +126.7% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $368,000 | -41.4% | 575,000 | -5.7% | 0.15% | -46.3% |
| OPTN | OPTINOSE INC | $333,000 | 0.0% | 90,970 | 0.0% | 0.14% | -8.0% | |
| MGTX | New | MEIRAGTX HLDGS PLC | $84,000 | – | 10,000 | +100.0% | 0.04% | – |
| IDYA | New | IDEAYA BIOSCIENCES INC | $22,000 | – | 1,500 | +100.0% | 0.01% | – |
| BLRX | BIOLINERX LTDsponsored ads | $16,000 | -23.8% | 16,667 | 0.0% | 0.01% | -22.2% | |
| Exit | AVALO THERAPEUTICS INC | $0 | – | -450,000 | -100.0% | -0.10% | – | |
| Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -68,900 | -100.0% | -0.15% | – | |
| FMTX | Exit | FORMA THERAPEUTICS HLDGS INC | $0 | – | -58,700 | -100.0% | -0.18% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -208,300 | -100.0% | -0.28% | – |
| Exit | HYPERFINE INC | $0 | – | -763,075 | -100.0% | -0.77% | – | |
| VSTM | Exit | VERASTEM INC | $0 | – | -1,590,000 | -100.0% | -0.83% | – |
| Exit | GINKGO BIOWORKS HOLDINGS INCclass a shares | $0 | – | -815,000 | -100.0% | -0.87% | – | |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -90,000 | -100.0% | -1.09% | – |
| MASS | Exit | 908 DEVICES INC | $0 | – | -166,406 | -100.0% | -1.54% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCclass a | $0 | – | -183,750 | -100.0% | -2.52% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -814,250 | -100.0% | -3.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.